The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Medical Solutions Group Regulatory News (AMS)

Share Price Information for Advanced Medical Solutions Group (AMS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 211.50
Bid: 211.50
Ask: 214.00
Change: 4.00 (1.93%)
Spread: 2.50 (1.182%)
Open: 200.00
High: 214.00
Low: 200.00
Prev. Close: 207.50
AMS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Update

10 Jan 2024 07:00

RNS Number : 1554Z
Advanced Medical Solutions Grp PLC
10 January 2024
 

10 January 2024

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

 

Full Year 2023 Trading Update

In line with expectations for FY 2023 and poised for strong growth in 2024

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, today announces its unaudited trading update for the year ended 31 December 2023 (the "Period"). The Group expects to announce its preliminary results on Wednesday 13 March 2024.

 

The Group is pleased to report Full Year 2023 results are expected to finish towards the middle of its published guidance ranges of £124-127 million for revenue and £25-27 million for adjusted profit before tax.

 

Furthermore, following the successful completion of a number of key strategic marketing initiatives and product launches during 2023 across the Group, AMS is primed to generate strong double-digit growth in 2024. Key progress includes:

 

· Re-vitalised US LiquiBand® distribution strategy - With all three US hospital distribution agreements in place since October 2023, the Group is pleased to report that the new strategy is having a positive impact on order intake. The new contracts are driving growth in both the $200 million small-wound market and the new, fast-growing $70 million long-wound market in which the pipeline of evaluations and conversions for LiquiBand® XL continues to increase rapidly and therefore the Board is confident of achieving record US LiquiBand® revenues in 2024.

· US launch of LiquiBandFix8®/LiquiFixTM - The US roll-out of LiquiBandFix8®/LiquiFixTM is progressing well. AMS's new commercial partner TELA Bio has completed an extensive training programme among its specialist hernia sales force and we are excited by the progress being made across a number of significant GPO systems in the US. Full in-market launch is forecast for late Q1 2024.

Chris Meredith, Chief Executive Officer of AMS, commented: "I am delighted with the strategic progress we have made across the Group in 2023, creating significant new opportunities for AMS. The completion of the new US LiquiBand® route to market strategy, the US Connexicon acquisition and the roll-out of LiquiBand® XL will support the delivery of record US LiquiBand® revenues in 2024 and sets us up strongly to deliver our target of doubling our market share over the next five years. With the US launch of LiquiFixTM progressing well and continued growth being generated from more established brands such as RESORBA® and ActivHeal®, we are confident that the Group will generate strong and sustainable growth in 2024 and in the long term." 

 

- End -

 

 

For further information, please contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

 

ICR Consilium

Tel: +44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

 

Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

HSBC Bank PLC (Broker)

Tel: +44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

 

 

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX? and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKLFBZFLXBBE
Date   Source Headline
1st Mar 20107:00 amRNSRule 2.10 Announcement
26th Feb 20102:51 pmRNSPossible Offer
26th Feb 201011:16 amRNSStatement re Possible Offer
11th Feb 20107:00 amRNSNotice of Results
1st Feb 20105:21 pmRNSTotal Voting Rights
28th Jan 20107:00 amRNSLiquiBand US Marketing Deal
19th Jan 20107:00 amRNSAppointment of COO
19th Jan 20107:00 amRNSSite Visit
7th Jan 20107:00 amRNSChange of Registered Office
5th Jan 20104:55 pmRNSHolding(s) in Company
5th Jan 20101:07 pmRNSHolding(s) in Company
5th Jan 20108:59 amRNSHolding(s) in Company
23rd Dec 20095:27 pmRNSHolding(s) in Company
17th Dec 20097:00 amRNSTrading Update
9th Dec 20097:00 amRNSActivHeal? Cuts Costs
30th Oct 200910:37 amRNSHolding(s) in Company
26th Oct 20097:00 amRNSSystagenix Product Launch
16th Oct 20094:03 pmRNSInitial LiquiBandT product introduced to US market
1st Oct 20097:00 amRNSAcquisition of Corpura
29th Sep 200912:01 pmRNSHoldings in Company
11th Sep 20095:36 pmRNSHolding(s) in Company
8th Sep 20097:00 amRNSInterim Results
10th Aug 20099:20 amRNS510(k) Approval for Silver Polyurethane
3rd Aug 20097:00 amRNSNotice of Interim Results
24th Jul 20094:16 pmRNSHolding(s) in Company
9th Jul 20097:00 amRNSLiquiband deal with Stryker
6th Jul 20094:22 pmRNSHolding(s) in Company
29th Jun 20099:37 amRNSHolding(s) in Company
10th Jun 20097:00 amRNSDirector Share Purchases
5th Jun 20097:00 amRNSGrowth Company Investor Show
3rd Jun 20092:36 pmRNSResult of AGM
3rd Jun 20097:00 amRNSAGM Statement
28th May 20095:36 pmRNSHolding(s) in Company
27th May 20097:00 amRNSInteguSeal reduces SSIs
22nd May 200911:14 amRNSPosting of Annual Report
30th Apr 20093:09 pmRNSBlocklisting Six Monthly Return
30th Apr 20093:04 pmRNSTotal Voting Rights
30th Apr 20093:01 pmRNSAdditional Listing
24th Apr 20097:00 amRNSDirector shareholdings
20th Apr 20094:42 pmRNSHolding(s) in Company
9th Apr 20094:01 pmRNSExceptional non-trading items
7th Apr 20099:43 amRNSDirector/PDMR Shareholding - Replacement
3rd Apr 20095:36 pmRNSHolding(s) in Company
3rd Apr 20093:57 pmRNSDirector/PDMR Shareholding
30th Mar 20093:43 pmRNSHolding(s) in Company
25th Mar 20099:00 amRNSHolding(s) in Company
17th Mar 20097:00 amRNSPreliminary Results
13th Mar 20094:52 pmRNSNomad and Broker Appointment
4th Mar 20097:00 amRNSNotice of Results
18th Feb 20099:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.